Company Overview and News
Steady path: Gas prices are displayed at a Mobil station in New York. Crude oil prices have risen steadily by more than 10. Shares in oil majors, including Exxon Mobil, have surged. — AP
KUALA LUMPUR: Perisai Petroleum Teknologi Bhd saw its share price jumped 30% in early trade Wednesday after releasing its second quarter results, posting profits of RM40.77mil.
KUALA LUMPUR: Shares of Perisai Petroleum Teknologi Bhd slipped 12% in early trade Wednesday after its unit’s landlord demanded a RM2.75mil payment for a breach of agreement.
Brent crude was 0.50% lower to US$55.72 per barrel at 3.48pm. Forex Ringgit up 0.24% to 4.2270 versus the US dollar at 3.58pm. Top foreign stories India seeks to raise up to US$1.7b from state-run reinsurer GIC Re’s IPO: State-run reinsurer General Insurance Corp of India (GIC Re)’s initial public offering of shares next week seeks to raise as much 113.7 billion rupees (US$1.7 billion) in what will be India’s second-biggest IPO.
MarketWatch: US stocks sold off on Thursday, with the S&P 500 recording its biggest daily percentage drop in three months as escalating worries about the Trump administration's ability to push through its economic agenda rattled investors. The DJIA ended down 274.14 points, or 1.24%, to 21,750.73, the S&P 500 lost 38.1 points, or 1.54%, to 2,430.01 and the Nasdaq dropped 123.20 points, or 1.94%, to 6,221.
UOB Asset Management (M) Bhd CEO Lim Suet Ling(pic) told StarBiz that investors are turning more cautious on the local debt market in the second half of this year pressured by rising global rates.
PETALING JAYA: Nam Cheong Group Bhd is the latest company that is unable to service its debts due to the prolonged downturn in the oil and gas (O&G) industry.
At 12.30pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) stood at 1,764.90, up 2.16 points, against last Friday's close of 1,762.74. — Reuters picKUALA LUMPUR, May 8 — Bursa Malaysia remained in positive territory at mid-day prompted by continuous buying momentum in selected heavyweights led by Maybank.
Conservative estimates suggest that in the wake of oil prices crashing in late 2014, the Malaysian oil and gas services and equipment (OGSE) sector contracted by at least 11%. Analysis of overall financials for the OGSE sector by the Malaysian Petroleum Resource Corp, an agency under the Prime Minister's Department, reveal that revenue for 2015 fell by 11%, while profits contracted by a severe 52.3%.
ALL is not well yet for Perisai Petroleum Teknologi Bhd, as the Malaysia-based upstream oil and gas services provider is hit with a triple whammy, hampering its return to profitability.
KUALA LUMPUR (March 8): Based on corporate announcements and news flow today, the companies in focus on Thursday (March 9) may include the following: Iskandar Waterfront City, Alam Maritim, Enra, LBS Bina, CIMB Group, GHL Systems, AmBank, Engtex and Wintoni.
THE Malaysian oil services firm that defaulted on US$89.3 million in bonds last October is trying again to settle its debts with bond holders.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
KUALA LUMPUR (Feb 27): The FBM KLCI struggled to to remain above the 1,700-point level at the midday break today as sellling persisted on Bursa Malaysia, despite the regional markets reversing earlier losses.
KUALA LUMPUR (Feb 27): Perisai Petroleum Teknologi Bhd’s shares were up as much as 1.5 sen or 21.4% this morning to 8.5 sen, as the Practice Note 17 company returned to the black in its second financial quarter ended Dec 31, 2016 (2QFY17).
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...